Skip to main content
SpringerLink
Log in

Breast Cancer Survival and in Vitro Tumor Response in the Extreme Drug Resistance Assay

  • Conference Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Purpose. To determine whether in vitro extreme drug resistance (EDR) assay results for patients with breast carcinoma were associated with clinical outcome after chemotherapy.

Patients and methods. EDR assays were performed on tumor tissue obtained from 103 newly diagnosed breast cancer cases. EDR scores of 2 for low, 1 for intermediate, or 0 for extreme drug resistance were determined for each agent tested. In vitro EDR scores for 4-hydroxycyclophosphamide (4HC) and doxorubicin were summed for patients treated with AC, or for 4HC and 5-FU for patients treated with CMF. Treatment selection was blinded to assay results.

Results. Median time to progression was significantly shorter for patients with extreme or intermediate in vitro resistance (n=55, 48 months), compared to patients with low in vitro resistance, (n=41, 100 months, p=0.022). Patients demonstrating extreme to intermediate drug resistance also showed poorer survival than the low resistance group (49.5 months vs. not reached, median follow-up 48 months, p=0.011). Summed EDR scores, stage, and number of lymph nodes were significantly associated with survival in univariate and multivariate analysis. Compared to EDR scores of 4, summed EDR scores of 0–1 and summed EDR scores of 2–3 were associated with a relative risk of death of 3.09 (95%, CI 1.05–9.06, Cox proportional hazards model, p=0.040) and 2.35 (95%, CI 1.07–5.15, Cox proportional hazards model, p=0.033), respectively.

Conclusion. Extreme drug resistance testing identified patients with individual patterns of drug resistance prior to therapy. In this cohort of breast cancer patients treated with chemotherapy, summed EDR scores were significantly associated with time to tumor progression and overall survival. EDR results may offer a method for optimizing treatment selection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Goldie JH, Coldman AJ: A mathematic model for relating the drug sensitivity of tumors to the spontaneous mutation rate. Cancer Treat Rep 63: 1727-1733, 1979

    Google Scholar 

  2. Goldie JH, Coldman AJ, Gadauskas GA: Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 66: 439-449, 1982

    Google Scholar 

  3. Fisher F, Brown AM, Dimitrov NV, Poisson R, Redmond C, Margolese RG, Bowman D, Wolmark N, Wickerham DL, Kardinal CG: Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared to months of cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer patients with tamoxifennonresponsive tumors. Results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8: 1483-1496, 1990

    Google Scholar 

  4. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 352: 930-942, 1998

    Google Scholar 

  5. Hutchins L, Green S, Ravdin P, Lew D, Martino S, Abeloff M, Lyss A, Henderson C, Allred C, Dakhil S, Pierce I, Goodwin W, Caton J, Rivkin S, Chapman R, Osborne K: CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer and a natural history follow-up study in low-risk node-negative patients: first results of Intergroup Trial INY 0102. Proc Am Soc Clin Oncol 17: 1a, 1998 (abstr 2)

    Google Scholar 

  6. Henderson IC, Berry D, Demetri G, Cirrincione C, Goldstein L, Martino S, Ingle JN, Cooper MR, Canellos G, Borden E, Fleming G, Holland JF, Graziano S, Carpenter J, Muss H, Norton L: Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from dose escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (pts) with node-positive primary breast cancer (BC) (abstract). Proc Am Soc Clin Oncol 17: 101a, 1998 (abstr390)

    Google Scholar 

  7. Carlson RW, Goldstein LJ, Gradishar WJ, Lichter AS, Mc-Cormick B, Moe RE, Theriault RL: NCCN breast cancer practice guidelines. The national comprehensive cancer network. Oncology 10(11 Suppl): 47-75, 1996

    Google Scholar 

  8. Anderson BO, Bensinger W, Cox CE, Davidson NE, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Lichter AS, Mc-Cormick B, Nabell LM, Reed EC, Silver SM, Smith ML, Somlo G, Theriault R, Ward JH, Winer EP, Wolff A: Update: NCCN Practice Guidelines for Breast Cancer. Oncology 14(11 Suppl): 33-49, 2000

    Google Scholar 

  9. Hortabagyi GN, Buzdar AU, Champlin R, Gajewski J, Holmes FA, Booser D, Valero V, Theriault RL: Lack of efficacy of adjuvant high dose (HD) tandem combination chemotherapy (CT) for high risk primary breast cancer-a randomized trial (abstract). Proc Am Soc Clin Oncol 17: 123a, 1998 (abstr 471)

    Google Scholar 

  10. Rodenhuis S, Richel DJ, van derWall E, Schornagel JH, Baars JW, Koning CC, Peterse JL, Borger JH, Nooijen WJ, Bakx R, Dalesio O, Rutgers E: Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet 352: 515-521, 1998

    Google Scholar 

  11. Peters W, Rosner G, Vredenburgh J, Shpall E, Crump M, Richardson P, Marks L, Cirrincione C, Wood W, Henderson I, Hurd D, Norton L: A prospective, randomized comparison of two doses combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): Preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13. Proc Am Soc Clin Oncol 18: 1a, 1999 (abstr 2)

    Google Scholar 

  12. Bezwoda WR: Randomized, controlled trial of high dose chemotherapy (HD-CNVp) vs. standard dose (CAF) chemotherapy for high risk, surgically treated, primary breast cancer. Proc Am Soc Clin Oncol 18: 2a, 1999 (abstr 4)

    Google Scholar 

  13. The Scandinavian Breast Study Group 9401: Results from a randomized adjuvant breast cancer study with high dose chemotherapy with CTCb supported by autologous bone marrow stem cells versus dose escalated and tailored FEC therapy. Proc Am Soc Clin Oncol 18: 2a, 1999 (abstr 3)

    Google Scholar 

  14. Lotz J-P, Curé H, Janvier M, Morvan F, Asselain B, Guillemot M, Laadem A, Maraninchi D, Gisselbrecht C, Roché H: High-Dose Chemotherapy (HD-CT) with hematopoietic stem cells transplantation (HSCT) for metastatic breast cancer: Results of the French Protocol Pegase 04. Proc Am Soc Clin Oncol 18: 43a, 1999 (abstr 161)

    Google Scholar 

  15. Stadtmauer EA, O'Neill A, Goldstein PG, Crilley P, Mangan KF, Ingle JN, Lazarus HM, Erban J, Sickles C, Glick JH: Phase III Randomized trial of high-dose chemotherapy (HDC) and stem cell support (SCT) shows no difference in overall survival or severe toxicity compared to maintenance chemotherapy with cyclophosphomide, methotrexate and 5-fluorouracil (CMF) for women with metastatic breast cancer who are responding to conventional induction chemotherapy: The Philadelphia Intergroup Study (PBT-01), ECOG, U. of Pennsylvania. Proc Am Soc Clin Oncol 18: 1a, 1999 (abstr 1)

    Google Scholar 

  16. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 351(9114): 1451-1467, 1998

    Google Scholar 

  17. Thor AD, Berry DA, Budman DR, Muss HB, Kute T, enderson IC, arcos M, rrincione C, Edgerton S, Allred C, Norton L, Liu ET: erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 90: 1346-1360, 1998

    Google Scholar 

  18. Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, Fisher ER, Lippman ME, Wickerham DL, Wolmark N: erbB-2 and response to doxorubicin patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 90: 1361-1370, 1998

    Google Scholar 

  19. Norton L, Slamon D, Leyland-Jones B, Wolter J, Fleming T, Eirmann W, Baselga J, Mendelsohn J, Bajamonde A, Ash M, Shak S: Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the Humanized Anti-HER2 Monoclonal Antibody Herceptin (H) in HER2-Overexpressing (HER2+) metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 18: 127a, 1999 (abstr 483)

    Google Scholar 

  20. Sledge GW Jr, Neuberg D, Ingle J, Martino S, Wood W: Phase III trial of doxorubicin vs. paclitaxel vs. doxorubicin+ paclitaxel as first-line therapy for metastatic breast cancer. Proc Am Soc Clin Oncol 16: 1a, 1997 (abstr 2)

    Google Scholar 

  21. Gammuci T, Piccart M, Brüning P, Klijn J, Biganzoli L, Houston S, Coleman R, Van Vreckem A, Cleall S, Curran D, Awada A, Paridaens R: Single agent taxol (T) versus doxorubic in (D) as first-line chemotherapy (CT) in advanced breast cancer (ABC): result of an EORTC randomized study with crossover. Proc Am Soc Clin Oncol 17: 11a, 1998 (abstr 428)

    Google Scholar 

  22. Ravdin P, Burris HA, Cook G, Eisenberg P, Kane M, Bierman WA, Mortimer J, Genevois E, Bellet RE: Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13: 2879-2885, 1995

    Google Scholar 

  23. Valero V, Holmes FA, Walters RS, Theriault RL, Esparza L, Fraschini G, Fonseca GA, Bellet RE, Buzdar AU, Hortobagyi GN: Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13: 2886-2894, 1995

    Google Scholar 

  24. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17: 485-493, 1999

    Google Scholar 

  25. Orr JW, Orr P, Kern D: Cost-effective treatment of women with advanced breast cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance. The Cancer J 5: 174-178, 1999

    Google Scholar 

  26. DeVita VT Jr: In: DeVita, Hellman, Rosenberg (eds), Cancer: Principles and Practice of Oncology. 5th edn, Lippincott-Raven Publishers, Philadelphia, 1997, 345 p

    Google Scholar 

  27. Fruehauf JP, Bosanquet AG: In vitro determination of drug response: A discussion of clinical applications, In: DeVita VT Jr, Hellman S, Rosenberg SA (eds), Principles and Practice of Oncology Updates, 4th edn, JB Lippincott, Philadelphia, PA, 1993, pp 1-16

    Google Scholar 

  28. Seidman AD, Reichman BS, Crown JP, Yao TJ, Currie V, Hakes TB, Hudis CA, Gilewski TA, Baselga J, Forsythe P, et al.: Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 13: 1152-1159, 1995

    Google Scholar 

  29. Seidman AD, Hudis CA, Norton L: Memorial Sloan Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer: from advanced disease to adjuvant therapy. Semin Oncol; 22(4 Suppl 8): 3-8, 1995

    Google Scholar 

  30. Mavroudis D, Malamos N, Alexopoulos A, Kourousis C, Agelaki S, Sarra E, Potamianou A, Kosmos C, Rigatos G, Giannakakis T, Kalbakis K, Apostolaki F, Vlachonicolis J, Kakolyris S, Samonis G, Georgoulias V: Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine. Ann Oncol 10: 211-215, 1999

    Google Scholar 

  31. Leung PP, Tannock IF, Oza AM, Puodziunas A, Dranitsaris G: Cost-Utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with Anthracyclineresistant breast cancer. J Clin Oncol 17: 3082-3090, 1999

    Google Scholar 

  32. Kern DH, Drogemuller CR, Kennedy MC, Hildebrand-Zanki SU, Tanigawa N, Sondak VK: Development of a miniaturized, improved nucleic acid-precursor incorporation assay for chemosensitivity testing of human solid tumors. Cancer Res 45: 5436-5441, 1985

    Google Scholar 

  33. Kern DH, Weisenthal LM: Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures. J Natl Cancer Inst 82: 582-588, 1990

    Google Scholar 

  34. Elledge RM, Clark GM, Hon J, Thant M, Belt R, Maguire YP, Brown J, Bartels P, Von Hoff DD: Rapid in vitro assay for predicting response to fluorouracil in patients with metastatic breast cancer. J Clin Oncol 17: 419-423, 1995

    Google Scholar 

  35. Cortazar P, Johnson BE: Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer. J Clin Oncol 17: 1125-1631, 1999

    Google Scholar 

  36. Cortazar P, Gazdar AF, Woods E, Russell E, Steinberg SM, Williams J, Ihde DC, Johnson BE: Survival of patients with limited-stage small cell lung cancer treated with individualized chemotherapy selected by in vitro drug sensitivity testing. Clin Cancer Res 3: 741-747, 1997

    Google Scholar 

  37. Gambino A, Favalli G, Salinaro, Pecorelli S: The use of Extreme Drug Resistance Assay in Gynecologic malignancies after failure of conventional chemotherapy. IGCS Oncol 17: F139a, 1999 (abstr)

    Google Scholar 

  38. Kurbacher CM, Bruckner HW, Cree IA, Bruckner HW, Brenne U, Kurbacher JA, Muller K, Ackermann T, Gilster TJ, Wilhelm LM, Engel H, Mallmann PK, Andreotti PE: A prospective clinical trial on individualized chemotherapy for recurrent ovarian cancer selected by the Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarion cancer. Anticancer Drugs 9: 51-57, 1998

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oncotech, Inc., CA

    Rita S. Mehta, Ing-Ru Yu, Ricardo J. Parker & John P. Fruehauf

  2. Chao Family Comprehensive Cancer Research Center, University of California, Irvine, Orange, CA, USA

    Rita S. Mehta, Christine E. McLaren, Khanh P. Nguyen, Kuo-Tung Li & John P. Fruehauf

  3. Center for Breast Health, OH

    Richard Bornstein

  4. Epidemiology Division, Department of Medicine, University of California, Irvine, CA, USA

    Christine E. McLaren

Authors
  1. Rita S. Mehta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard Bornstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ing-Ru Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ricardo J. Parker
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Christine E. McLaren
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Khanh P. Nguyen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kuo-Tung Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. John P. Fruehauf
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mehta, R.S., Bornstein, R., Yu, IR. et al. Breast Cancer Survival and in Vitro Tumor Response in the Extreme Drug Resistance Assay. Breast Cancer Res Treat 66, 225–237 (2001). https://doi.org/10.1023/A:1010604502627

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1010604502627

Search

Navigation